Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

Suzetrigine: Vertex continues to enroll and dose patients with diabetic peripheral neuropathy (DPN) in a Phase 3 pivotal trial of suzetrigine. Following the December 2024 release of Phase 2 results ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the ...

The companies will focus on next-generation gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. Credit: da-kuk via Getty Images. Vertex Pharmaceuticals and Orna ...